Brief: Medicenna Announces First Patient Dosed In ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA

Medicenna Therapeutics

13/02/2024 12:55

Feb 13 (Reuters) - Medicenna Therapeutics Corp
 MDNA.TO :
    * MEDICENNA ANNOUNCES FIRST PATIENT DOSED IN ABILITY-1 STUDY
OF
MDNA11 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS
WITH ADVANCED SOLID TUMORS
    * MEDICENNA ANNOUNCES FIRST PATIENT DOSED IN ABILITY-1 STUDY
OF
MDNA11 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS
WITH ADVANCED SOLID TUMORS

Source text for Eikon:  ID:nGNX3WgY2S 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))